16th Jul 2024 11:30
Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - Says trading in the first half of 2024 was strong, as it expects revenue to have climbed 16% to USD16.4 million from USD14.1 million a year prior. "The BioRinse segment continued to deliver solid growth driven by increased efficiencies, while the commercial reorganisation of the dCELL segment continued to show benefits, demonstrating robust growth within the period," Tissue Regenix says. It will report its full half-year results on September 10. Read More